Akari Therapeutics Plc (NASDAQ:AKTX) filed a definitive proxy statement (DEF 14A) with the Securities and Exchange Commission on February 03, 2026.
The Healthcare company's proxy statement provides information for shareholders ahead of the annual meeting, including board nominations, executive compensation, and proposals for shareholder vote.
Akari Therapeutics Plc's stock currently trades at $0.23 with a market capitalization of $7.2K.